Key result
Subpressor angiotonin and pitressin sustain microvascular flow in hemorrhagic shock, outperforming standard pressor agents.
Why the study?
Therapeutic procedures for hemorrhagic shock syndrome require evaluation based on their ability to correct vascular decompensatory episodes linked to refractoriness to blood transfusion.
Does the addition of angiotonin or pitressin to transfusion medium improve peripheral circulation in dogs with hemorrhagic shock syndrome?
Population
Dogs with hemorrhagic shock syndrome
Comparison
Pressor drugs versus angiotonin and pitressin added to transfusion medium
Design
Preclinical study
Authors
Loading...
May enhance peripheral flow in canine hemorrhagic shock; leaves open translation to human resuscitation.
Does the addition of angiotonin or pitressin to transfusion medium improve peripheral circulation in dogs with hemorrhagic shock syndrome?
In a canine model of hemorrhagic shock, subpressor doses of angiotonin and pitressin improved peripheral blood flow, highlighting the importance of terminal vascular bed changes in circulatory collapse.
Benjamin William Zweifach (1950) studied Hemorrhagic shock syndrome. Pressor drugs, angiotonin, and pitressin was evaluated on Peripheral circulation criteria (vasomotion, responsiveness to vasoconstrictor stimuli, tone of arterioles and venules, and capillary blood flow). Angiotonin and pitressin in subpressor concentrations brought sustained improvement in omental blood flow in dogs with hemorrhagic shock, unlike standard pressor drugs.
Synapse has enriched one closely related paper. Consider it for comparative context: